1 / 20

Malaria

Malaria. Tintinalli’s Chap. 148. In General…. It is a protozoan disease caused by the bite of the Anopheles mosquito. Four species of the Plasmodium genus infect humans.(P.Vivax, P.Ovale, P.Malariae, P.Falciparum)

samara
Download Presentation

Malaria

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Malaria Tintinalli’s Chap. 148

  2. In General… • It is a protozoan disease caused by the bite of the Anopheles mosquito. • Four species of the Plasmodium genus infect humans.(P.Vivax, P.Ovale, P.Malariae, P.Falciparum) • P.Falciparum is the most deadly, and is becoming increasingly resistant to antimalarial medications.

  3. In General… • Transmission occurs in greater portions of Central and South America, the Caribbean, sub Saharan Africa, the Indian subcontinent, Southeast Asia, the Middle East, and Oceania. • Any patient returning from the tropics with an unexplained fever should be suspected.

  4. Pathophysiology: • The anopheline (female) mosquito bites releasing sporozoites into the host’s blood which are carried to liver. • Asexual reproduction begins in hepatic parenchymal cells, and they rupture. • Merozoites (daughters) are released and invade erythrocytes.

  5. Pathophysiology: • They mature in the erythrocytes into trophozoites and schizonts until the cell lyses and the cycle continues. • Several cycles later, the merozoites develop into sexual gametocytes which later develop into sporozoites which can infect another host.

  6. Pathophysiology: • P. Falciparum, P.Vivax, P.Ovale, and P.Malariae differ in…(see table 148-2) • Incubation period • Reproduction time • RBC preference • Morphologic features

  7. Pathophysiology: • The asexual intraerythrocytic parasite causes the symptoms and pathophysiologic consequences. • It can be transmitted by direct transfusion of infected blood or transplacentally from mother to fetus.

  8. Clinical Features: • Prodrome of malaise, myalgia, headache, low grade fevers, and chills • Some may have cough, chest pain, abdominal pain, arthralgia or diarrhea. • Eventually, the patient may have severe chills, high grade fevers, tachycardia, nausea, orthostatic dizziness, and weakness.

  9. Physical Exam: • Pts appear acutely ill with high fevers, tachycardia & tachypnea • Splenomegaly • Tender abdomen • Liver enlargement • Lymphadenopathy • Maculopapular rash

  10. Labs: • Normochromic normocytic anemia (hemolysis) • Normal or mildly depressed leukocyte count • Thrombocytopenia • Elevated ESR • Elevated LDH • Liver and renal function abnormalities • Hyponatremia, hypoglycemia • False pos. VDRL

  11. Complications: • Splenic enlargement, or rupture • Autoimmune glomerulonephritis • Cerebral malaria • Respiratory failure • Lactic acidosis • Profound hypoglycemia

  12. Diagnosis: • Giemsa stained thick and thin blood smears to view parasites • At certain stages of the infection the parasites may be undetectable. • If suspicious of malaria, failure to see the parasites on the stain is not a reason to not treat.

  13. Diagnosis: • To exclude malaria completely, repeated smears should be done twice daily for two to three days. • To determine prognosis: look for degree of parasitemia and whether P. Falciparum is present.

  14. P. Falciparum: • Look for small ring forms with double chromatin knobs within erythrocyte, and crescent shaped gametocyte. • This should be managed in a hospital setting.

  15. Treatment: • Most cases can be handled in an ambulatory setting. • Those that should be hospitalized include: those infected with P.Falciparum, infants, pregnant women, those with significant chronic medical problems.

  16. Treatment: • Uncomplicated infection with P.Vivax, P.Ovale, P.Malariae and Chloroquine sensitive P.Falciparum: • Chloroquine phosphate plus Primaquine phosphate • See Table 148-4 for dosing schedules

  17. Treatment: • Uncomplicated infection with chloroquine resistant P.Falciparum: • Quinine sulfate plus doxycycline plus or minus Pyrimethamine Sulfadoxine • Or, Mefloquine plus doxycycline or Atovaquone-Proguanil

  18. Treatment: • Complicated infection with chloroquine resistant P.Falciparum: • Quinidine Gluconate plus Doxycycline • See table 148-5 for side affects of meds • Parasite should decrease within 24-48hrs. • No asexual forms should be detected 3-4 days after treatment. • Gametocytes may persistent, but do not mean treatment failure.

  19. Treatment: • Clinical relapses usually occur unless Primaquine is used. • Primaquine should not be given to those that are glucose-6-phosphate dehydrogenase deficient. • Primaquine is not needed with P.Falciparum due to the absence of dormant asexual forms in the liver.

  20. Prevention: • Anti-mosquito measures • Antimalarial drugs • Pyrethrum containing insect spray • Insect repellent containing DEET • Appropriate chemoprophylaxis (see table 148-6) • Malaria vaccines are still in trials

More Related